EN 
BS
HR
IT
ME
MK
SL
SR
Labena Group’s Contract Research and Analytics divison for Pharma & Biotech proudly announces a significant expansion of its service portfolio with new capabilities in bioprocess development and analytical characterization for antibody therapeutics and recombinant proteins.
The Ljubljana-based facility now integrates advanced process development, characterisation, and analytical support across all stages of biotechnological development and production — from drug discovery/development, upstream process development to downstream purification , including also drug substance and final drug product testing. This expansion positions Labena Groups’s CRO as a comprehensive development partner for biologics, including monoclonal antibodies and other recombinant therapeutics.
Equipped with state-of-the-art process and analytical technologies, including sophisticated chromatography systems, advanced and high-throughput biophysical analytics capabbilities, as well as AMBR®250 24-way HT, wave bioreactors, and many more, the facility enables precise, scalable, and reproducible upstream and downstream process development. Dedicated laboratories for microbiologyical testing with its sterility testing capabilities further strengthen the analytical capabilities, supporting comprehensive testing and regulatory compliance.
To complement its robust and compliant infrastructure, the site operates on a robust digital platform with upgraded hardware and software systems for secure data processing and analysis in line with pharmaceutical data integrity standards.
»Labena grows together with Slovenia’s rapidly developing biotech infrastructure and the growing investments by major pharmaceuitcal and biopharmaceutical players into the local biotech envifronemnt« said Borut Čeh, CEO and Managing Director of Labena Group. »Through this expansion, we are strengthening our ability to support biopharma with advanced analytics and bioprocess development — enabling our partners to accelerate biologics innovation with quality and flexibility.«
With these enhanced capabilities, Labena Group reinforces its position as a vertically integrated provider of biopharmaceutical services, combining GMP-compliant analytics, process development, and characterization under one roof. The expansion also opens new opportunities for Labena to further expand its capabilities and business internationally, supporting biopharma partners across Europe and globally in their pursuit of innovative and agile development solutions.
Acknowledgment of Support
Labena Group sincerely acknowledges the support of Ministry of the Economy, Tourism, and Sport and SPIRIT Slovenia, the national agency for entrepreneurship, internationalization, foreign investment, and technology, whose contribution has been an important enabler in the realization of this project. SPIRIT Slovenia’s continuous commitment to fostering innovation and strengthening the competitiveness of Slovenian companies is highly valued, as it contributes to the advancement of the national biotech ecosystem and encourages international collaboration within the life sciences sector.
The project was selected for co-financing under the Public Call for Promoting Large Investments to Increase Productivity and Competitiveness in the Republic of Slovenia (JR INVEST2022-NOO).
The investment is co-financed by the European Union through the Recovery and Resilience Facility – NextGenerationEU, as part of Slovenia’s national Recovery and Resilience Plan.
About Labena Groups’s CRO
Contract Research and Analytics divison of Labena Group, is a Contract Research Organisation (CRO) providing comprehensive analytical services for small molecules, biologics, and advanced therapies, and process development and characterization services for biologics. Labena supports pharmaceutical drug development from early discovery through final market-ready product. Leveraging deep expertise and flexibility, Labena Group’s CRO partners with biotech and pharmaceutical companies to accelerate drug development.
